IP Library › Granted Patent US 12,351,628
Granted Patent B2
US 12,351,628 · App. 17/335,677 · Granted Jul 8, 2025

Modified membrane spanning proteins and methods for the preparation and use thereof

Inventor: Mauro Mileni (San Diego, CA)
Assignee: ABILITA THERAPEUTICS, INC.
C07K16/28C07K14/705C12N15/1037C12N15/1079C12N15/1093A61K38/00
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12,351,628
App. No.
17/335,677
Granted
Jul 8, 2025
Kind
B2
Abstract

In accordance with the present invention, there are provided functionally modulated tool receptors which are useful for drug discovery and development. In certain aspects and embodiments as described herein, a sophisticated and powerful approach has been designed that allows the rapid development of enhanced receptors, while simultaneously exploring millions of possibilities for improved properties with respect to such properties as protein expression, homogeneity, stabilization, conformational and activation pathway selectivity, antigenicity, immunogenicity, and the like. Indeed, the new methodology described herein represents a breakthrough by leveraging a full range of combinatorial amino acid replacements, in multiple positions simultaneously, in order to generate modified membrane-spanning proteins.

Claims (33)

1. A method of modulating one or more functional properties of a membrane-spanning protein, said method comprising:

(a) generating a first polynucleotide library from a starting polynucleotide that encodes the membrane-spanning protein, wherein a sufficient number of bases of said starting polynucleotide are randomly modified so as to modulate the one or more functional properties of the membrane-spanning protein,

(b) generating a second polynucleotide library from said first polynucleotide library by DNA shuffling, said second polynucleotide library comprising a modified polynucleotide encoding a modified membrane-spanning protein comprising said one or more modulated functional properties,

(c) inserting the modified polynucleotides of said second polynucleotide library into a construct comprising:

a signal sequence,

a first marker sequence, wherein said first marker sequence is in-frame with said modified polynucleotide, is downstream of said modified polynucleotide, and encodes a polypeptide that overcomes the sensitivity of a host cell to the presence of a first selective pressure agent or condition and the polypeptide is fused to said modified membrane-spanning protein, and

a second marker sequence, wherein said second marker sequence is in-frame and downstream of said signal sequence, but upstream of said modified polynucleotide, is different from the first marker sequence and encodes a polypeptide that overcomes the sensitivity of a host cell to the presence of a second selective pressure agent or condition, and is fused to said modified membrane-spanning protein, thereby producing modified polynucleotide-containing constructs,

(d) transforming a plurality of host cells with the modified polynucleotide-containing constructs to obtain a plurality of transformed host cells;

(e) culturing the transformed host cells in the presence of said first and second selective pressure agents/conditions, wherein the concentration/condition levels of said first and second selective pressure agents/conditions are higher than the concentration/condition levels of said first and second selective pressure agents/conditions used for culturing an equivalent host cell transformed with the starting polynucleotide;

(f) selecting a host cell from step (e) that survives exposure to said first and second selective pressure agents/conditions; and

(g) identifying the modified polynucleotide-containing construct(s) contained therein;

wherein the surviving host cells from step (f) express the modified membrane-spanning protein having the one or more modulated functional properties relative to the membrane-spanning protein encoded by the starting polynucleotide.

2. The method of claim 1 wherein said one or more modulated functional properties are selected from the group consisting of an increased level of expression of said modified membrane-spanning protein, an increased stability of said modified membrane-spanning protein, an increased homogeneity of said modified membrane-spanning protein, an increased crystallizability of said modified membrane-spanning protein, an increased antigenicity of said modified membrane-spanning protein, an increased immunogenicity of said modified membrane-spanning protein, a modulated conformational selectivity and/or activation pathway selectivity of said modified membrane-spanning protein.

3. The method of claim 2 , wherein said one or more modulated functional properties comprise an increased level of expression of said modified membrane spanning protein, wherein said increase is at least 5 fold.

4. The method of claim 2 , wherein said one or more modulated functional properties comprise an increased stability of said modified membrane spanning protein, wherein said stability is an increase in thermostability.

5. The method of claim 4 , wherein said increase in thermostability is stability at an increase of at least 7° C.

6. The method of claim 1 wherein said membrane-spanning protein is a G-protein coupled receptor (GPCR).

7. The method of claim 1 , wherein said GPCR is a GPR55 or a Neurotensin receptor 1 (NTSR1).

8. The method of claim 1 , wherein said first selective pressure agent is a first antibiotic.

9. The method of claim 1 , wherein said second selective pressure agent is a second antibiotic.

10. The method of claim 1 , wherein said modified membrane- spanning protein comprises at least 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, or 15 modified amino acid residues relative to the membrane-spanning protein.

11. The method of claim 1 , further comprising isolating the modified polynucleotide containing constructs.

12. The method of claim 7 , further comprising verifying the occurrence of said one or more modulated functional properties by:

inserting the modified polynucleotide containing constructs into a suitable host cell, expressing said modified polynucleotide, and

characterizing the modified membrane-spanning protein encoded by the modified polynucleotide.

13. The method of claim 12 , further comprising isolating the modified membrane-spanning protein.

14. The method of claim 1 , further comprising:

randomly reverting said modified residues back,

re-selecting in the presence of selective pressure agent(s)/conditions(s), and

re-characterizing the modulated functional properties in order to identify a minimum working set of mutations.

15. The method of claim 1 wherein the host cell is selected from the group consisting of a bacterial cell, a yeast cell, an insect cell and a mammalian cell.

16. The method of claim 1 , wherein the first marker sequence encodes a thioredoxin 1 or a beta-lactamase.

17. The method of claim 1 , wherein the second marker sequence is a kanamycin resistance gene or a gentamicin resistance gene.

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jun 2, 2021
From: MILENI, MAURO
To: ABILITA BIO, INC.
Reel/Frame 056413/0894 →
Continuity (4)
Continuation 16411059 · May 13, 2019
Continuation 14928128 · Oct 30, 2015
Provisional Application 62073554 · Oct 31, 2014
Related Publication 20210363239A1 · Nov 25, 2021
References Cited (54)
US 7912654B2 · Kobilka et al. · 2011 [cited by applicant]
US 9127287B2 · Hall et al. · 2015 [cited by applicant]
US 1027349A1 · Mileni · 2019 [cited by applicant]
US 10287349B2 · Mileni · 2019 [cited by examiner]
US 11053312B2 · Mileni · 2021 [cited by examiner]
US 20020045234A1 · Squirrell et al. · 2002 [cited by applicant]
US 20040091975A1 · Midoh et al. · 2004 [cited by applicant]
US 20040214317A1 · Battaglino et al. · 2004 [cited by applicant]
US 20040265274A1 · Wei et al. · 2004 [cited by applicant]
US 20060275288A1 · Grihalde et al. · 2006 [cited by applicant]
US 20100099169A1 · Bowie et al. · 2010 [cited by applicant]
US 20100304432A1 · O'Keefe et al. · 2010 [cited by applicant]
US 20110028700A1 · Heal et al. · 2011 [cited by applicant]
US 20110046351A1 · Weir et al. · 2011 [cited by applicant]
US 20120270230A1 · Henderson et al. · 2012 [cited by applicant]
US 20120302461A1 · Camps et al. · 2012 [cited by applicant]
US 20130052646A1 · Tripathi et al. · 2013 [cited by applicant]
US 20140256918A1 · Chu et al. · 2014 [cited by applicant]
EP 2450445A1 · 2012 [cited by applicant]
WO WO2008068534A2 · 2008 [cited by applicant]
WO WO2009081136A2 · 2009 [cited by applicant]
WO WO2010078290A2 · 2010 [cited by applicant]
WO WO2010149964A2 · 2010 [cited by applicant]
WO WO2011033322A2 · 2011 [cited by applicant]
WO WO2012022928A2 · 2012 [cited by applicant]
WO WO2012098413A1 · 2012 [cited by applicant]
WO WO2012120315A2 · 2012 [cited by applicant]
WO WO2012137012A1 · 2012 [cited by applicant]
WO WO2013021206A2 · 2013 [cited by applicant]
WO WO2014026136A2 · 2014 [cited by applicant]
WO WO2016070022A1 · 2016 [cited by applicant]
WO WO2017192743A1 · 2017 [cited by applicant]
Brown et al. Pharmacology of GPR55 in Yeast and Identification of GSK494581A as a Mixed-Activity Glycine Transporter Subtype 1 Inhibitor and GPR55 Agonist. J Pharmacol Exp Ther 337:236-246 (2011). [cited by applicant]
Hibbert et al. Directed evolution strategies for improved enzymatic performance. Microb Cell Fact 4:29 (6 pgs.) (2005). [cited by applicant]
Hutchings et al. Monoclonal anti-β1-adrenergic receptor antibodies activate G protein signaling in the absence of β-arrestin recruitment. mAbs 6(1):246-261 (2014). [cited by applicant]
Klenk et al. A generic selection system for improved expression and thermostability of G protein-coupled receptors by directed evolution. Sci REp 6:21294 (2016). [cited by applicant]
Myers et al. A Yeast Genetic Screen Reveals a Critical Role for the Pore Helix Domain in TRP Channel Gating. Neuron 58:362-373 (2008). [cited by applicant]
PCT/US2015/58280 International Preliminary Report on Patentability dated May 11, 2017. [cited by applicant]
PCT/US2015/58280 International Search Report and Written Opinion dated Mar. 30, 2016. [cited by applicant]
PCT/US2017/030874 International Search Report and Written Opinion dated Jul. 27, 2017. [cited by applicant]
Sarkar et al. Directed evolution of a G protein-coupled receptor for expression, stability, and binding selectivity. PNAS USA 105:14808-14813 (2008). [cited by applicant]
Scarselli et al. Multiple Residues in the Second Extracellular Loop Are Critical for M3 Muscarinic Acetylcholine Receptor Activation. J Bio Chem 282:7385-7396 (2007) . [cited by applicant]
Schlegel et al. Bacterial-based membrane protein production. Biochim Biophys Acta 1843(8):1739-1749 (2013). [cited by applicant]
Schlegel et al. Revolutionizing membrane protein overexpression in bacteria : Revolutionizing membrane protein overexpression in bacteria. Microbial Biotechnology 3(4):403-411 (2009). [cited by applicant]
Seitz et al. Enhancing the stability and solubility of the glucocorticoid receptor ligand-binding domain by high-throughput library screening. J Mol Biol 403:562-577 (2010). [cited by applicant]
Shibata et al. Thermostabilization of the neurotensin receptor NTS1. J Mol Biol 390:262-277 (2009). [cited by applicant]
Standfuss et al. Crystal structure of a thermally stable rhodopsin mutant. J Mol Biol 372:1179-1188 (2007). [cited by applicant]
U.S. Appl. No. 14/928,128 Office Action dated May 31, 2018. [cited by applicant]
U.S. Appl. No. 14/928,128 Office Action dated Nov. 1, 2017. [cited by applicant]
U.S. Appl. No. 16/098,821 Office Action dated Jan. 17, 2020. [cited by applicant]
Tucker, et al., “Purification of a rat neurotensin receptor expressed in [cited by applicant]
Skretas, et al., “Simple Genetic Selection Protocol for Isolation of Overexpressed Genes That Enhance Accumulation of Membrane-Integrated Human G Protein-Coupled Receptors in [cited by applicant]
Jo, et al., “Engineering therapeutic antibodies targeting G-protein-coupled receptors” Experimental & Molecular Medicine (2016) p. 2-9. [cited by applicant]
Massey-Gendel, et al. “Genetic selection system for improving recombinant membrane protein expression in [cited by applicant]